Clinical Trials · NCT02698410
Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Ipsen
- Enrollment
- 40
- Start date
- Jul 2016
- Locations
- 10 sites, Italy
- Primary endpoint
- Disease Control Rate (DCR) Assessed Locally at Month 9